18th Dec 2015 08:20
LONDON (Alliance News) - Hutchison China MediTech Ltd said Friday that its drug research and development subsidiary has begun a phase III trial of sulfatinib in China for patients with extra-pancreatic neuroendocrine tumours.
Top line results for this trial are expected in 2018. Additionally, a second smaller phase III trial for the same drug is expected to be initiated in China imminently for the same patient group. Top-line results form this second trial are expected in 2017.
Shares in Hutchison China MediTech were down 1.2% at 2,625.00 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed